AxoGen, Inc. Announces Release Date of First Quarter 2013 Results and Conference Call

AxoGen to release Q1 2013 results on April 30, 2013

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Alachua, FL (PRWEB) April 24, 2013

AxoGen, Inc. (OTCBB: AXGN) a leading regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, announced that it will release its financial results for the period ended March 31, 2013, after the close of U.S. financial markets on April 30, 2013.

An accompanying conference call hosted by Karen Zaderej, Chief Executive Officer, and Greg Freitag, Chief Financial Officer, to discuss results will be held at 10:00 a.m. ET, on Wednesday, May 1, 2013. Dial in information for the live call is as follows:

Conference dial-in:            877-709-8150
International dial-in:            201-689-8354
Conference Name:            AxoGen 1Q 2013 Results Call
Conference ID:            00413262
Conference Call Webcast:        http://www.axogeninc.com/investors.html

Following the live call, a replay will be available on the Company's website, http://www.axogeninc.com, under “Investors.”

About AxoGen, Inc.
AxoGen (AXGN) is a regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. The Company’s innovative approach to regenerative medicine has resulted in first-in-class products that will define their product categories. AxoGen’s products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa ECM coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. For more information, visit our website at http://www.axogeninc.com.

AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL. To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html.


Contact